RRR-α-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus

American Journal of Clinical Nutrition

Volumn 63, Issue 5, 1996, Pages 753-759

  Fuller, Cindy J ^a   Chandalia, Manisha ^a   Garg, Abhimanyu ^a   Grundy, Scott M ^a   Jialal, Ishwarlal ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diabetes; lipid peroxidation; low density lipoprotein; vitamin E

Indexed keywords

ALPHA TOCOPHEROL; FATTY ACID; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PROTEIN GLYCOSYLATION; VITAMIN INTAKE;

EID: 0029939297     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/63.5.753     Document Type: Article

References (59)

1. Witztum JL, Steinberg D Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
2. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983;24:1070-6.
3. Cybulski MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1990;251:788-91.
4. Kume N, Cybulski MI, Gimbrone MA Jr Lysophosphatidyl-choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992;90:1138-44.
5. Jacobs M, Plane F, Bruckdorfer KR. Native and oxidized low density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta Br J Pharmacol 1990,100:21-6.
6. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988;241.215-8.
7. Palinski W, Rosenfeld ME, Yiä-Herttuala, et al. Low-density lipoprotein undergoes oxidative modifications in vivo. Proc Nad Acad Sci U S A 1989;86:1372-6.
8. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A 1987;84:5928-31.
9. Björkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy V, Berglund L, Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 1991;11:15-22.
10. Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 1992;94:153-9.
11. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524.
12. Jennings PE, Jones AF, Florkowski CM, Lunec J, Barnett AH. Increased diene conjugates in diabetic subjects with microangiopathy. Diabet Med 1987,4:452-6.
13. Mooradian AD. Increased serum conjugated dienes in elderly diabetic patients. J Am Geriatr Soc 1991;39:571-4.
14. Velazquez E, Winocour PH, Kesteven P, Alberti KGMM, Laker MF. Relation of lipid peroxide to macrovascular disease in type 2 diabetes. Diabet Med 1991;8:752-8.
15. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993;71:26B-31B.
16. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification by a superoxide-dependent pathway. J Clin Invest 1994;94:771-8.
17. Chari SW, Nath N, Rathi A. Glutathione and its redox system in diabetic polymorphonuclear leukocytes. Am J Med Sci 1984;287: 14-5.
18. Sinclair AJ, Girling AJ, Gray L, LeGuen C, Lunec J, Barnett AH. Disturbed handling of ascorbic acid in diabetic patients with and without microangiopathy during high dose ascorbate supplementation. Diabetologia 1991;34:171-5
19. Nath N, Chari SN, Rathi AB. Superoxide dismutase in diabetic polymorphonuclear leukocytes. Diabetes 1984;33.586-9.
20. Karpen CW, Cataland S, O'Donsio TM, Panganamala RV. Interrelation of platelet vitamin E and thromboxane synthesis in type I diabetes mellitus. Diabetes 1984;33:239-43.
21. Barakat HA, Carpenter JW, McLendon VD, et al. Influence of obesity, impaired glucose tolerance, and non-insulin-dependent diabetes on low-density lipoprotein structure and composition: possible link between hyperinsulinemia and atherosclerosis. Diabetes 1990;39:1527-33.
22. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense low-density lipoproteins to oxidative modification in subjects with the atherogenesis lipoprotein phenotype: pattern B. Am J Med 1993;94:350-6.
23. Kitahara M, Eyre J II, Lynch RE, Rallison ML, Hill HR. Metabolic activity of diabetic monocytes. Diabetes 1980;29:251-6.
24. Wu G, Marliss EB. Enhanced glucose metabolism and respiratory burst in peritoneal macrophages from spontaneously diabetic BB rats. Diabetes 1993;42:520-9.
25. Bowie A, Owens D, Collins P, Johnson A, Tomkin G. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993;102:63-7.
26. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994;43:1010-4.
27. Babiy AV, Gebicki JM, Sullivan DR, Willey K. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem Pharmacol 1992;43:995-1000.
28. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM Diabetes 1995;44:60-6.
29. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H. Effect of oral supplementation with d α-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 1991;33:1325-32.
30. Jialal I, Fuller CJ, Huet BA. The effect of α-tocopherol supplementation on LDL oxidation: a dose-response study. Arterioscler Thromb Vasc Biol 1995;15:190-8.
31. Princen HMG, van Poppel G, Vogelezang C, Buytenhek R, Kok FJ. Supplementation with vitamin E but not β-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro: effect of cigarette smoking. Arterioscler Thromb 1992;12:554-62.
32. Reaven PD, Witztum JL. Comparison of supplementation of RRR-α-tocopherol in humans. Arterioscler Thromb 1993;13:601-8.
33. Reaven PD, Herold DA, Barnett J, Edelman S. Effects of vitamin E on susceptibility of low-density lipoprotein and low-denbity lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care 1995;18:807-16.
34. Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylalion in diabetics: new prospect for prevention of diabetic complications. Diabetes Care 1991; 14:68-72.
35. Paolisso G, Giugliano D, D'Amore A, et al. Daily vitamin E supplements improve control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 1993;16:1433-7.
36. Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'Onofrio F. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr 1993,57:650-6.
37. Sullivan K, Raskin P. Evaluation of a new automated affinity-chromatographic method for the measurement of glycated hemoglobin. Diabetes Res Clin Pract 1991;13:103-6.
38. Sobel DO, Shakir EM. Determination of glycated plasma proteins in normal and diabetic subjects utilizing phenylaminoboronic acid columns. Diabete Metab 1987;13.575-81.
39. Lipid Research Clinics Program, Manual of laboratory operations: lipid and lipoprotein analysis. Washington, DC: Department of Health and Human Services, 1984, [National Institutes of Health publication no. F5-628.]
40. Arnaud J, Fortis I, Blachier S, Kia D, Favier A. Simultaneous determination of retinol, α-tocopherol, and β-carotene in serum by isocratic high-performance liquid chromatography. J Chromatogr 1991;572: 103-16.
41. Thurnham D, Davies J, Crump B, Situnayake R, Davis M. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 1986;23:514-20.
42. Omaye S, Turnbull J, Sauberlich HE. Selected methods for the determination of ascorbic acid in animal cells, tissues, and fluids. Methods Enzymol 1979;62:3-12.
43. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1986;27:114-20.
44. Jialal I, Vega GL, Grundy SM. Physiological levels of ascorbate inhibit the oxidative modification of LDL. Atherosclerosis 1990;82: 185-91.
45. Lowry OH, Rosebrough NJ, Farr A, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
46. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67-75.
47. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar AY, Jürgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989;30:627-30.
48. Jialal I, Scaccini C. Antioxidants and atherosclerosis. Curr Opin Lipidol 1992;3:324-8.
49. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1994;329:977-86.
50. Gey KF, Puska P, Jordon P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991;53(suppl):326S-34S.
51. Manson JE, Gaziano JM, Jonas MA, Hennekens CH. Antioxidants and cardiovascular disease: a review. J Am Coll Nutr 1993;12:426-32.
52. Riemersma RA, Wood DA, MacIntyre CCA, Ekon RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, E and carotene Lancet 1991;337:1-5.
53. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and risk of coronary disease in women. N Engl J Med 1993;328:1444-9.
54. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.
55. Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995;273:1849-54.
56. Shoff SM, Mares-Perlman JA, Cruickshanks KJ, Klein R, Klein BEK, Ritter LL. Glycosylated hemoglobin concentrations and vitamin E, vitamin C. and β-carotene intake in diabetic and nondiabetic older adults. Am J Clin Nutr 1993;58:412-6.
57. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JE. Levastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992;41:229-35.
58. National Research Council. Recommended dietary allowances. 10th ed. Washington DC: National Academy Press, 1989.
59. Kappus H, Diplock AT. Tolerance and safety of vitamin E. a toxicological position report. Free Radic Biol Med 1992;13:55-74.